New study checks kidney impact on hepatitis b drug
NCT ID NCT07342881
First seen Jan 28, 2026 · Last updated May 10, 2026 · Updated 17 times
Summary
This study looks at how a single dose of the experimental drug pevifoscorvir sodium (ALG-000184) is processed by the body in people with different levels of kidney function. About 30 adults with chronic hepatitis B and either severe, mild, moderate, or normal kidney function will take part. The goal is to understand safety and drug levels, not to treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Genesis Clinical Trials
RECRUITINGTampa, Florida, 33603, United States
Contact Email: •••••@•••••
-
Orlando Clinical Research Center
RECRUITINGOrlando, Florida, 32809, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.